Preparing for PrEP: estimating the size of the population eligible for HIV pre-exposure prophylaxis among men who have sex with men in England

被引:6
作者
Mitchell, Holly D. [1 ]
Desai, Sarika [1 ]
Mohammed, Hamish [1 ]
Ong, Koh Jun [1 ]
Furegato, Martina [1 ]
Hall, Victoria [1 ]
Desai, Monica [1 ]
Saunders, John Michael [1 ,2 ]
Hughes, Gwenda [1 ]
Field, Nigel [1 ,3 ]
Gill, O. Noel [1 ]
机构
[1] Publ Hlth England, Natl Infect Serv, Blood Safety Hepatitis Sexually Transmitted Infec, London NW9 5EQ, England
[2] UCL, Ctr Clin Res Infect & Sexual Hlth, Inst Global Hlth, London, England
[3] UCL, Inst Global Hlth, Ctr Mol Epidemiol & Translat Res, London, England
关键词
gay men; HIV; surveillance; policy; public health; CLINICS; RISK; MSM;
D O I
10.1136/sextrans-2019-054009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives The size of the population of men who have sex with men (MSM) who may be eligible for HIV pre-exposure prophylaxis (HIV-PrEP) in England remains unknown. To plan for a national PrEP implementation trial, we estimated the number of MSM attending sexual health clinics (SHCs) that may be eligible for HIV-PrEP in England. Methods Sexually transmitted infection (STI) surveillance data from 2010 to 2015 from the GUMCAD surveillance system were used to estimate the annual number of HIV-negative MSM who may be eligible for HIV-PrEP in England. Based on national eligibility criteria, we identified HIV-negative MSM attending SHCs with a HIV-negative test in the past year and used diagnosed bacterial STI (past year) in this group as a proxy for condomless sex and eligibility for HIV-PrEP. We estimated HIV incidence per 100 person-years (py) in these groups in 2014. Results During 2010-2015, the number of HIV-negative MSM attending SHCs with a HIV-negative test in the past year doubled from 14 643 to 29 023, and HIV incidence in this group was 1.9 (95% CI 1.6 to 2.2) per 100 py in 2014. In the same period, the subgroup with a bacterial STI diagnosis (past year), and therefore considered potentially eligible for HIV-PrEP in this analysis, increased from 4365 (30%) to 10 276 (35%). HIV incidence in this subgroup was 3.3 (95% CI 2.7 to 4.0) per 100 py in 2014. Conclusions In 2015, approximately 10 000 HIV-negative MSM were considered potentially eligible for HIV-PrEP based on clinic history in GUMCAD. These data were used to inform the initial recruitment target for the PrEP Impact Trial and will inform future evaluations at a population level.
引用
收藏
页码:484 / 487
页数:4
相关论文
共 16 条
[1]  
[Anonymous], PREP IMP TRIAL PRAGM
[2]   HIV incidence in an open national cohort of men who have sex with men attending sexually transmitted infection clinics in England [J].
Desai, S. ;
Nardone, A. ;
Hughes, G. ;
Delpech, V. ;
Burns, F. ;
Hart, G. ;
Gill, O. N. .
HIV MEDICINE, 2017, 18 (09) :615-622
[3]  
Grulich AE, 2018, LANCET
[4]  
Health Protection Scotland and Information Services Division, 2019, IMPL HIV PREP SCOTL
[5]   NHS to fund large trial of pre-exposure prophylaxis for HIV prevention [J].
Mayor, Susan .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 355
[6]   Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial [J].
McCormack, Sheena ;
Dunn, David T. ;
Desai, Monica ;
Dolling, David I. ;
Gafos, Mitzy ;
Gilson, Richard ;
Sullivan, Ann K. ;
Clarke, Amanda ;
Reeves, Iain ;
Schembri, Gabriel ;
Mackie, Nicola ;
Bowman, Christine ;
Lacey, Charles J. ;
Apea, Vanessa ;
Brady, Michael ;
Fox, Julie ;
Taylor, Stephen ;
Antonucci, Simone ;
Khoo, Saye H. ;
Rooney, James ;
Nardone, Anthony ;
Fisher, Martin ;
McOwan, Alan ;
Phillips, Andrew N. ;
Johnson, Anne M. ;
Gazzard, Brian ;
Gill, Owen N. .
LANCET, 2016, 387 (10013) :53-60
[7]   Eligibility for PrEP among MSM attending GUM clinics in the UK [J].
Miltz, Ada Rose ;
Cambiano, Valentina ;
Lampe, Fiona C. ;
Sewell, Janey ;
Speakman, Andrew ;
Phillips, Andrew N. ;
Ivens, Daniel R. ;
Asboe, David ;
Collins, Simon ;
Brady, Michael ;
Nwokolo, Nneka C. ;
Rodger, Alison J. .
SEXUALLY TRANSMITTED INFECTIONS, 2017, 93 (08) :571-571
[8]   On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection [J].
Molina, J. -M. ;
Capitant, C. ;
Spire, B. ;
Pialoux, G. ;
Cotte, L. ;
Charreau, I. ;
Tremblay, C. ;
Le Gall, J. -M. ;
Cua, E. ;
Pasquet, A. ;
Raffi, F. ;
Pintado, C. ;
Chidiac, C. ;
Chas, J. ;
Charbonneau, P. ;
Delaugerre, C. ;
Suzan-Monti, M. ;
Loze, B. ;
Fonsart, J. ;
Peytavin, G. ;
Cheret, A. ;
Timsit, J. ;
Girard, G. ;
Lorente, N. ;
Preau, M. ;
Rooney, J. F. ;
Wainberg, M. A. ;
Thompson, D. ;
Rozenbaum, W. ;
Dore, V. ;
Marchand, L. ;
Simon, M. -C. ;
Etien, N. ;
Aboulker, J. -P. ;
Meyer, L. ;
Delfraissy, J. -F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (23) :2237-2246
[9]  
Nash S, 2018, Progress towards ending the HIV epidemic in the United Kingdom: 2018 report
[10]  
NHS England, PREP TRIAL UPD JUN 2